Stockreport

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

DaVita Inc.  (DVA) 
Last davita inc. earnings: 2/10 04:01 pm Check Earnings Report
US:NYSE Investor Relations: investors.davita.com/investor-relations
PDF Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership with Alebund Pharmaceutical [Read more]